“It’s really fascinating how the field is expanding,” Klein says.
“[Genomic testing is] going to be a routine part of prostate cancer care and urologic cancer care going forward,” Eric A. Klein, MD, says in this video. Klein is the Chairman of the Glickman Urological & Kidney Institute and a staff member in the Taussig Cancer Institute at Cleveland Clinic.
Enzalutamide granted approval in EU for nmHSPC
April 24th 2024The approval is supported by data from the phase 3 EMBARK trial, which demonstrated that enzalutamide with or without leuprolide prolonged metastasis-free survival compared with leuprolide alone in patients with high-risk biochemically recurrent nmHSPC.